Biotech News

Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Lineage Cell Therapeutics (LCTX)Lineage Cell TherapeuticsEarnings

Acquired NeuroAirmid Therapeutics, Inc. and Its Cell Therapy Product Candidate for Huntington’s Disease, Currently Enrolling in a Phase 1b/2a Clinical Trial (REGEN4HD) Announced Issuance of a Patent Covering its AlloSCOPE™ “5D” Technology, a Component of Its AlloSCOPE Cell Manufacturing Platform

Related news

Lineage Cell Therapeutics

Pluripotent Cell Therapy Company Lineage Cell Therapeutics develops allogeneic, off-the-shelf cell replacements using its AlloSCOPE pluripotent stem-cell engineering and manufacturing platform. OpRegen RG6501, formerly OpRegen, is a retinal pigment epithelium cell replacement therapy partnered with Roche and Genentech for geographic...

Recent company news

Stock data

Close
0.82 USD
Market cap
301.65M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States